HomeGeneticsConditionAutosomal dominant hypocalcemia
Back to Condition
Autosomal dominant hypocalcemia
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Autosomal dominant hypocalcemia

Autosomal dominant hypocalcemia is a genetic condition characterized by low blood calcium levels, often resulting in muscle irritability, cramping, or seizures, though many affected individuals remain asymptomatic.

Overview

Autosomal dominant hypocalcemia is characterized by low levels of calcium in the blood (hypocalcemia). Affected individuals may also experience an imbalance of other molecules, including high levels of phosphate (hyperphosphatemia) or low levels of magnesium (hypomagnesemia). Some individuals also have low levels of parathyroid hormone (hypoparathyroidism), which is responsible for regulating blood calcium. While these imbalances can cause various symptoms, approximately half of those affected have no associated health problems.

Symptoms

The most common features include:

  • Muscle spasms in the hands and feet (carpopedal spasms)
  • Muscle cramping
  • Prickling or tingling sensations (paresthesias)
  • Twitching of the nerves and muscles (neuromuscular irritability)

More severely affected individuals may develop seizures, typically in infancy or childhood. In some cases, symptoms only manifest during episodes of illness or fever. Additionally, some individuals develop high levels of calcium in their urine (hypercalciuria), which can lead to calcium deposits in the kidneys (nephrocalcinosis) or kidney stones (nephrolithiasis). Abnormal calcium deposits may also form in the brain, typically in the basal ganglia.

A small percentage of individuals may exhibit features of Bartter syndrome, including low potassium (hypokalemia), low magnesium, high levels of the hormone aldosterone (hyperaldosteronism), and an elevated blood pH (metabolic alkalosis).

Causes

The condition is distinguished by two genetic types:

  • Type 1: Caused by mutations in the CASR gene.
  • Type 2: Caused by mutations in the GNA11 gene.

The CASR gene provides instructions for the calcium-sensing receptor (CaSR), which monitors blood calcium levels. The GNA11 gene produces Gα11, a signaling protein that works with CaSR. Mutations in these genes lead to protein overactivity, causing the body to perceive calcium levels as higher than they are and preventing the normal processes that would increase calcium in the blood. This results in persistent hypocalcemia.

Inheritance

This condition is inherited in an autosomal dominant pattern, meaning one copy of the altered gene in each cell is sufficient to cause the disorder. While most cases are inherited, some result from new (de novo) mutations in the gene in people with no family history of the disorder.

Frequently Asked Questions

Diagnosis involves measuring serum calcium, phosphate, magnesium, and parathyroid hormone (PTH) levels. A low calcium with normal or low PTH, combined with high phosphate or low magnesium, suggests the condition. Genetic testing for CASR or GNA11 mutations confirms the diagnosis.
Treatment focuses on maintaining normal calcium levels with oral calcium supplements and active vitamin D (calcitriol). If hypercalciuria is present, thiazide diuretics can reduce urinary calcium loss. Regular monitoring of calcium, phosphate, and kidney function is essential to adjust therapy and prevent seizures.
Kidney imaging (ultrasound or CT) can detect nephrocalcinosis or stones. Elevated urinary calcium (hypercalciuria) is a risk factor; measuring 24‑hour urine calcium helps assess this. Early detection allows for dietary modifications and medication adjustments to reduce stone formation.
balanced diet with adequate calcium (about 1000‑1200 mg/day for children) and vitamin D is important. Limiting high‑phosphate foods (e.g., processed meats, cola drinks) can help. Staying hydrated reduces stone risk, and avoiding excessive dairy or calcium supplements without medical guidance prevents hypercalciuria.===
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab